Emerging combination therapies for the management of multiple myeloma: the role of elotuzumab

References

• FairfieldHFalankCAveryLReaganMRMultiple myeloma in the marrow: pathogenesis and treatmentsAnn N Y Acad Sci201613641325127002787
   PubMed Web of Science ®Google Scholar
• MorganGJWalkerBADaviesFEThe genetic architecture of multiple myelomaNat Rev Cancer201212533534822495321
   PubMed Web of Science ®Google Scholar
• JemalASiegelRWardEHaoYXuJThunMJCancer statistics, 2009CA Cancer J Clin200959422524919474385
   PubMed Web of Science ®Google Scholar
• ShahNCallanderNGangulySHematopoietic stem cell transplantation for multiple myeloma: guidelines from the American Society for Blood and Marrow TransplantationBiol Blood Marrow Transplant20152171155116625769794
   PubMed Web of Science ®Google Scholar
• AnreddyNHazlehurstLATargeting intrinsic and extrinsic vulnerabilities for the treatment of multiple myelomaJ Cell Biochem20171181152527261328
   PubMed Web of Science ®Google Scholar
• BianchiGMunshiNCPathogenesis beyond the cancer clone(s) in multiple myelomaBlood2015125203049305825838343
   PubMed Web of Science ®Google Scholar
• KumarSKLeeJHLahuertaJJRisk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group studyLeukemia201226114915721799510
   PubMed Web of Science ®Google Scholar
• LaubachJPMoreauPSan-MiguelJFRichardsonPGPanobinostat for the treatment of multiple myelomaClin Cancer Res201521214767477326362997
   PubMed Web of Science ®Google Scholar
• ScottAMWolchokJDOldLJAntibody therapy of cancerNat Rev Cancer201212427828722437872
   PubMed Web of Science ®Google Scholar
• de WeersMTaiYTvan der VeerMSDaratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumorsJ Immunol201118631840184821187443
   PubMed Web of Science ®Google Scholar
• RichardsonPGMoreauPLaubachJPMaglioMELonialSSan-MiguelJDeacetylase inhibitors as a novel modality in the treatment of multiple myelomaPharmacol Res201611718519127884726
   PubMed Web of Science ®Google Scholar
• AroraAScholarEMRole of tyrosine kinase inhibitors in cancer therapyJ Pharmacol Exp Ther2005315397197916002463
   PubMed Web of Science ®Google Scholar
• ZhangLFokJHDaviesFEHeat shock proteins in multiple myelomaOncotarget2014551132114824675290
   PubMed Web of Science ®Google Scholar
• MoreauPRichardsonPGCavoMProteasome inhibitors in multiple myeloma: 10 years laterBlood2012120594795922645181
   PubMed Web of Science ®Google Scholar
• BianchiGRichardsonPGAndersonKCPromising therapies in multiple myelomaBlood2015263300310
   Web of Science ®Google Scholar
• HsiEDSteinleRBalasaBCS1, a potential new therapeutic antibody target for the treatment of multiple myelomaClin Cancer Res20081492775278418451245
   PubMed Web of Science ®Google Scholar
• HazlehurstLAArgilagosRFEmmonsMCell adhesion to fibronectin (CAM-DR) influences acquired mitoxantrone resistance in U937 cellsCancer Res20066642338234516489039
   PubMed Web of Science ®Google Scholar
• HazlehurstLADaltonWSMechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignanciesCancer Metastasis Rev2001201–2435011831646
   PubMed Web of Science ®Google Scholar
• HazlehurstLADamianoJSBuyuksalIPledgerWJDaltonWSAdhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR)Oncogene200019384319432710980607
   PubMed Web of Science ®Google Scholar
• BouchonACellaMGriersonHLCohenJIColonnaMActivation of NK cell-mediated cytotoxicity by a SAP-independent receptor of the CD2 familyJ Immunol2001167105517552111698418
   PubMed Web of Science ®Google Scholar
• TaiYTDillonMSongWAnti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieuBlood200811241329133717906076
   PubMed Web of Science ®Google Scholar
• PalumboASonneveldPPreclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myelomaExpert Rev Hematol20158448149126070331
   PubMed Web of Science ®Google Scholar
• PalumboACavalloFLenalidomide in the treatment of plasma cell dyscrasia: state of the art and perspectivesHaematologica201398566066123633539
   PubMed Web of Science ®Google Scholar
• LentzschSO’SullivanAKennedyRCCombination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation studyBlood2012119204608461322451423
   PubMed Web of Science ®Google Scholar
• WangMDimopoulosMAChenCLenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposureBlood2008112124445445118799726
   PubMed Web of Science ®Google Scholar
• GandhiAKKangJCaponeLDexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell functionCurr Cancer Drug Targets201010215516720088798
   PubMed Web of Science ®Google Scholar
• De LuisiAFerrucciAColucciaAMLenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myelomaClin Cancer Res20111771935194621307145
   PubMed Web of Science ®Google Scholar
• GrossCCBrzostowskiJALiuDLongEOTethering of intercellular adhesion molecule on target cells is required for LFA-1-dependent NK cell adhesion and granule polarizationJ Immunol201018552918292620675589
   PubMed Web of Science ®Google Scholar
• BarberDFFaureMLongEOLFA-1 contributes an early signal for NK cell cytotoxicityJ Immunol200417363653365915356110
   PubMed Web of Science ®Google Scholar
• BalasaBYunRBelmarNAElotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin- 2 and TNF- α pathwaysCancer Immunol Immunother2015641617325287778
   PubMed Web of Science ®Google Scholar
• ChenDFrezzaMSchmittSKanwarJDouQPBortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectivesCurr Cancer Drug Targets2011323925321247388
   PubMed Web of Science ®Google Scholar
• ShiJTricotGJGargTKBortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myelomaBlood200811131309131717947507
   PubMed Web of Science ®Google Scholar
• van RheeFSzmaniaSMDillonMCombinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myelomaMol Cancer Ther2009892616262419723891
   PubMed Web of Science ®Google Scholar
• ZonderJAMohrbacherAFSinghalSA phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myelomaBlood2012120355255922184404
   PubMed Web of Science ®Google Scholar
• LonialSVijRHarousseauJLElotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myelomaJ Clin Oncol201230161953195922547589
   PubMed Web of Science ®Google Scholar
• JakubowiakAJBensonDMBensingerWPhase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myelomaJ Clin Oncol201230161960196522291084
   PubMed Web of Science ®Google Scholar
• RichardsonPGJagannathSMoreauPElotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple-myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation studyLancet Hamatol2015212e516e527
   PubMed Web of Science ®Google Scholar
• LonialSDimopoulosMPalumboAElotuzumab therapy for relapsed or refractory multiple myelomaN Engl J Med2015373762163126035255
   PubMed Web of Science ®Google Scholar
• DimopoulosMALonialSWhiteDEloquent-2 update: a phase 3, randomized, open-label study of elotuzumab in combination with lenalidomide/dexamethasone in patients with relapsed/refractory multiple myeloma-3-year safety and efficacy follow-upBlood20151262328
   Google Scholar
• MateosMVGranellMOriolAElotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myelomaBr J Haematol2016175344845627434748
   PubMed Web of Science ®Google Scholar
• JakubowiakAOffidaniMPégourieBRandomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MMBlood2016127232833284027091875
   PubMed Web of Science ®Google Scholar
• WangYSanchezLSiegelDSWangMLElotuzumab for the treatment of multiple myelomaJ Hematol Oncol2016915527417553
   PubMed Web of Science ®Google Scholar
• CostelloCAn update on the role of daratumumab in the treatment of multiple myelomaTher Adv Hematol201781283728042457
   PubMed Web of Science ®Google Scholar
• UsmaniSZWeissBMPlesnerTClinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myelomaBlood20161281374427216216
   PubMed Web of Science ®Google Scholar